دورية أكاديمية
Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer.
| العنوان: | Efficacy of docetaxel combined with oxaliplatin and fluorouracil against stage III/IV gastric cancer. |
|---|---|
| المؤلفون: | Yu YJ; Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China., Sun WJ; Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China., Lu MD; Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China., Wang FH; Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China., Qi DS; Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China., Zhang Y; Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China., Li PH; Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China., Huang H; Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China., You T; Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China., Zheng ZQ; Yao-Jun Yu, Wei-Jian Sun, Ming-Dong Lu, Fei-Hai Wang, Dan-Si Qi, Yi Zhang, Pi-Hong Li, He Huang, Tao You, Zhi-Qiang Zheng, NO H09 Disease Dist., Department of General Surgery, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325003, Zhejiang Province, China. |
| المصدر: | World journal of gastroenterology [World J Gastroenterol] 2014 Dec 28; Vol. 20 (48), pp. 18413-9. |
| نوع المنشور: | Clinical Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group Original Publication: Beijing : WJG Press, c1998- |
| مواضيع طبية MeSH: | Gastrectomy* , Neoadjuvant Therapy*/adverse effects, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Stomach Neoplasms/*drug therapy, Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant ; Diagnostic Imaging/methods ; Docetaxel ; Drug Administration Schedule ; Female ; Fluorouracil/administration & dosage ; Humans ; Karnofsky Performance Status ; Male ; Middle Aged ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Remission Induction ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery ; Taxoids/administration & dosage ; Time Factors ; Treatment Outcome |
| مستخلص: | Aim: To investigate the clinical efficacy and toxic effects of neoadjuvant chemotherapy using docetaxel combined with oxaliplatin and fluorouracil for treating stage III/IV gastric cancer. Methods: A total of 53 stage III/IV gastric cancer patients were enrolled into the study and treated with neoadjuvant chemotherapy. Two of the cases were excluded. The program was as follows: 75 mg/m(2) docetaxel and 85 mg/m(2) oxaliplatin on day 1 and 1500 mg/m(2) fluorouracil on days 1 to 3 for three weeks. Results: The tumour changes, postoperative remission rate, changes in the symptoms and adverse reactions were observed. The overall clinical efficacy (complete remission + partial remission) of the neoadjuvant chemotherapy was 62.7%. R0 radical resection was performed on 60.8% of the patients, with a remission rate (pathological complete response + pathological subtotal response + pathological partial response) of 74.2%. The Karnofksy score improved in 42 cases. The toxicity reactions mostly included myelosuppression, followed by gastrointestinal mucosal lesions, nausea, vomiting and diarrhoea. Conclusion: Neoadjuvant chemotherapy consisting of docetaxel combined with oxaliplatin and fluorouracil is effective for stage III/IV gastric cancer. However, the treatment is associated with a high incidence of bone marrow suppression, which should be managed clinically. |
| References: | Eur J Surg Oncol. 2013 Aug;39(8):814-22. (PMID: 23755989) Cochrane Database Syst Rev. 2007;(2):CD005047. (PMID: 17443566) BMC Cancer. 2013;13:75. (PMID: 23394629) G Chir. 2010 Apr;31(4):147-50. (PMID: 20444330) Med Oncol. 2012 Sep;29(3):1707-10. (PMID: 22033912) Cancer Biol Med. 2012 Jun;9(2):128-32. (PMID: 23691468) J Natl Compr Canc Netw. 2013 May 1;11(5):531-46. (PMID: 23667204) Cancer. 1999 Apr 1;85(7):1484-9. (PMID: 10193937) Chin Med J (Engl). 2012 Jun;125(12):2144-50. (PMID: 22884144) Eur J Surg Oncol. 2004 Aug;30(6):643-9. (PMID: 15256239) Cancer Chemother Pharmacol. 2013 May;71(5):1309-14. (PMID: 23463482) Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1895-8. (PMID: 19102417) Radiat Oncol. 2013;8:6. (PMID: 23286735) Am J Surg. 2011 Nov;202(5):605-11. (PMID: 21824594) Lancet Oncol. 2009 Feb;10(2):191-5. (PMID: 19185837) Oncologist. 2013;18(3):281-7. (PMID: 23429739) CA Cancer J Clin. 2013 Jan;63(1):11-30. (PMID: 23335087) J Clin Oncol. 1989 Sep;7(9):1318-26. (PMID: 2769330) J Clin Oncol. 2011 May 1;29(13):1715-21. (PMID: 21444866) World J Gastroenterol. 2012 Dec 21;18(47):7026-32. (PMID: 23323004) Oncol Res. 2013;20(7):327-32. (PMID: 23879173) J Surg Oncol. 2012 May;105(6):535-41. (PMID: 22006649) Expert Rev Gastroenterol Hepatol. 2012 Apr;6(2):199-208; quiz 209. (PMID: 22375525) |
| فهرسة مساهمة: | Keywords: Docetaxel; Gastric cancer; Neoadjuvant chemotherapy; Oxaliplatin |
| المشرفين على المادة: | 0 (Organoplatinum Compounds) 0 (Taxoids) 04ZR38536J (Oxaliplatin) 15H5577CQD (Docetaxel) U3P01618RT (Fluorouracil) |
| تواريخ الأحداث: | Date Created: 20150107 Date Completed: 20150914 Latest Revision: 20181202 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC4277980 |
| DOI: | 10.3748/wjg.v20.i48.18413 |
| PMID: | 25561810 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2219-2840 |
|---|---|
| DOI: | 10.3748/wjg.v20.i48.18413 |